Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOSET vs KYNMOBI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
FDA-approved: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Off-label: Parkinson's disease, hyperprolactinemia, acromegaly, neuroleptic malignant syndrome.
Treatment of hypomobility, off episodes, and end-of-dose wearing-off in patients with advanced Parkinson disease,Off-label: Treatment of erectile dysfunction
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
Primarily hepatic via cytochrome P450 3A4 (CYP3A4). Inactive metabolites are excreted mainly in feces (80%) and urine (2-10% unchanged).
Extensively metabolized in the liver by glucuronidation via UGT1A1 and UGT2B7; also undergoes sulfation. N-demethylation via CYP1A2 and CYP3A4 may occur. No active metabolites identified.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
~20–30% bound, primarily to albumin.
Apomorphine is approximately 90% bound to plasma proteins, primarily albumin.
0.5–1.0 L/kg, indicating moderate distribution into tissues.
The volume of distribution is approximately 200 L (about 2.9 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Oral: ~65–75% due to first-pass metabolism.
Bioavailability of apomorphine is low and variable after oral administration (<5%). Subcutaneous administration provides 100% bioavailability. Sublingual film (KYNMOBI) has a bioavailability of approximately 18% relative to subcutaneous injection.
Contraindicated in patients with e GFR <30 m L/min/1.73 m2. For e GFR 30-50 m L/min/1.73 m2: maximum dose 0.8 mg daily.
No specific dose adjustment provided; use caution in severe renal impairment (Cr Cl <30 m L/min) as data limited.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
No specific dose adjustment provided; use caution in Child-Pugh Class C as data limited.
Not approved for pediatric patients. Safety and efficacy in patients <18 years have not been established.
Safety and effectiveness in pediatric patients have not been established.
Start at 0.8 mg once daily; titrate slowly due to increased risk of orthostatic hypotension and hypoglycemia. Consider renal function and comorbidities.
No specific geriatric dose adjustment; pharmacokinetics similar to younger adults; monitor for hypotension and hallucinations.
None.
KYNMOBI can cause serious adverse reactions, including severe nausea and vomiting, symptomatic orthostatic hypotension (particularly with concomitant antihypertensives), syncope, QT prolongation, and hallucinations/psychosis. It should not be used with serotonergic drugs due to risk of serotonin syndrome.
Risk of hypotension, especially at initiation of therapy; monitor blood pressure.,May cause somnolence and dizziness; advise patients not to drive or operate machinery until effects are known.,Use with caution in patients with cardiovascular disease, especially those with angina or recent myocardial infarction.,May exacerbate psychotic disorders; use caution in patients with a history of psychosis.,Fibrotic complications (pulmonary, pericardial, retroperitoneal fibrosis) have been reported with ergot-derived dopamine agonists; monitor for symptoms.,Discontinue if signs of cardiac valvulopathy occur.
Orthostatic hypotension/syncope; nausea/vomiting (pretreat with antiemetic); hallucinations/psychosis; impulse control disorders; dyskinesias; coronary and cerebral ischemia; QT prolongation; priapism; somnolence/sudden sleep onset; falls; cardiac valvulopathy (due to ergot-like activity); potential for abuse (dopaminergic dysregulation syndrome).
Hypersensitivity to bromocriptine or any component of the formulation.,Concomitant use with CYP3A4 inducers (e.g., rifampin, anticonvulsants) or inhibitors (e.g., azole antifungals, macrolide antibiotics).,Severe ischemic heart disease or peripheral vascular disorders.,Syncopal migraine or history of myocardial infarction with residual arrhythmias.,Uncontrolled hypertension.,Lactation: inhibits lactation, do not use in women with pregnancy or nursing unless essential.
Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, triptans) due to risk of serotonin syndrome; severe hepatic impairment; history of QT prolongation or concomitant QT-prolonging drugs; hypersensitivity to apomorphine or its components; use of 5-HT3 antagonists (e.g., ondansetron) for antiemesis (risk of profound hypotension).
Avoid alcohol and alcohol-containing products. No specific food interactions; take with or without food. Maintain adequate hydration.
No specific food interactions are reported; however, administer on an empty stomach or at least 30 minutes before or after meals to optimize absorption. Avoid grapefruit juice as it may increase apomorphine levels. Alcohol should be avoided due to additive sedative and hypotensive effects.
First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause maternal hypoglycemia which can affect fetus.
Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times the maximum human dose, respectively, on a mg/m² basis). No fetal malformations were observed. However, embryolethality and decreased fetal body weight occurred at maternally toxic doses in rabbits. Use during pregnancy only if potential benefit justifies potential risk to the fetus; first trimester risks are unknown.
Not recommended; no data on excretion in human milk. M/P ratio unknown.
It is not known whether apomorphine is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Monitor glucose closely; dose adjustments may be needed due to altered pharmacokinetics in pregnancy (increased clearance). Start at lowest effective dose; titrate based on glycemic response.
Pharmacokinetic changes during pregnancy may alter apomorphine clearance, although specific data are lacking. No dosing adjustment studies have been conducted. Use caution and monitor clinical response; dose adjustment may be necessary based on efficacy and tolerability, but no standard recommendation exists.
Monitor for hypoglycemia, especially in elderly patients or those with renal impairment. Cycloserine may accumulate in renal insufficiency; dose reduction is necessary if Cr Cl < 50 m L/min. Watch for neuropsychiatric effects (seizures, psychosis, depression) and discontinue if severe. Pyridoxine 50-100 mg daily is recommended to reduce neurotoxicity. Avoid alcohol due to increased seizure risk.
KYNMOBI (apomorphine sublingual film) is a rapid-onset, non-ergoline dopamine agonist for acute, intermittent treatment of OFF episodes in Parkinson disease. Onset of action occurs within 15-30 minutes. Administer film under the tongue and allow to dissolve completely; do not swallow saliva until dissolved. Nausea and vomiting are common pre-treatment with an antiemetic (e.g., trimethobenzamide) for at least 2 days prior. Monitor for hypotension, syncope, and QT prolongation. Avoid use with 5-HT3 antagonists (e.g., ondansetron) due to risk of profound hypotension. Do not use with apomorphine injection as it may lead to cumulative adverse effects.
Take exactly as prescribed; do not miss doses or double up.,Report any signs of rash, confusion, dizziness, or unusual behavior immediately.,Avoid alcohol completely while on this medication.,If you have kidney problems, your dose may need adjustment.,Take pyridoxine (vitamin B6) as directed to lower risk of side effects.,Do not drive or operate heavy machinery if you feel drowsy or dizzy.,Complete the full course of therapy even if you feel better.
Place the film under your tongue and let it dissolve completely. Do not chew, swallow, or move the film with your tongue.,Do not eat or drink until the film has fully dissolved to ensure proper absorption.,Take KYNMOBI only at the first sign of an OFF episode to improve mobility.,You may experience nausea and vomiting; your doctor may prescribe an antiemetic to take before your first dose.,Avoid alcohol, as it may increase sedation and hypotension.,Do not drive or operate machinery until you know how KYNMOBI affects you, as it may cause dizziness, drowsiness, or sudden sleep onset.,Report any unusual urges (gambling, sexual, spending) to your doctor as these can occur with dopamine agonists.,Do not use this medicine more than 5 times per day or more often than every 2 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOSET vs KYNMOBI, answered by our medical review team.
CYCLOSET is a Dopamine Agonist / Antidiabetic that works by Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.. KYNMOBI is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOSET and KYNMOBI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOSET is: 1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.. The standard adult dose of KYNMOBI is: Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOSET and KYNMOBI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOSET is classified as Category C. First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause mate. KYNMOBI is classified as Category C. Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.